SCHEMBL402963

SCHEMBL402963

O=S(=O)(O)OCC1C[C@@H](OCc2ccccc2)C(OS(=O)(=O)O)CO1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCHE P06276 2/20 0.41
REN P00797 1/20 0.36
CTSV O60911 1/20 0.36
CTSL P07711 1/20 0.36
CTSB P07858 1/20 0.36
CTSS P25774 1/20 0.36
CTSK P43235 1/20 0.36
CTSC P53634 1/20 0.36
CTSF Q9UBX1 1/20 0.36
KLK7 P49862 6/20 0.35
KLK5 Q9Y337 3/20 0.35
NAE1 Q13564 1/20 0.34
UBA3 Q8TBC4 1/20 0.34
PSEN1 P49768 1/20 0.34
PSEN2 P49810 1/20 0.34
APH1B Q8WW43 1/20 0.34
NCSTN Q92542 1/20 0.34
APH1A Q96BI3 1/20 0.34
PSENEN Q9NZ42 1/20 0.34
SLC6A2 P23975 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL403453 0.83 BCHE (0.39) BCHERENCTSVCTSLCTSB
SCHEMBL14478945 0.81 BCHE (0.45) BCHECTSVCTSLCTSBCTSS
SCHEMBL404025 0.81 BCHE (0.45) BCHECTSVCTSLCTSBCTSS
SCHEMBL402461 0.81 KLK7 (0.41) BCHERENKLK7KLK5NAE1
SCHEMBL404382 0.78 KLK7 (0.42) BCHECTSVCTSLCTSBCTSS
SCHEMBL20643004 0.76 BCHE (0.48) BCHEPSEN1PSEN2APH1BNCSTN
SCHEMBL402622 0.76
SCHEMBL402446 0.74 CTSV (0.41) BCHECTSVCTSLCTSBCTSS
SCHEMBL403095 0.73
SCHEMBL19976411 0.72 BCHE (0.46) BCHEKLK7KLK5MGLL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120065153-A1 AZASUGAR DERIVATIVES, HEPARANASE INHIBITORS, METHOD FOR PREPARING SAME, COMPOSITIONS CONTAINING SAME, USE THEREOF SANOFI-AVENTIS (FR) 2012-03-15 US disclosed
US-20070270354-A1 Azasugar derivatives, heparanase inhibitors, method for preparing same, compositions containing same, use thereof SANOFI-AVENTIS (FR) 2007-11-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120065153-A1 AZASUGAR DERIVATIVES, HEPARANASE INHIBITORS, METHOD FOR PREPARING SAME, COMPOSITIONS CONTAINING SAME, USE THEREOF HPSE, HAAO, HEXD BCHE 1419/4885REN 508/4885CTSV 1018/4885
US-20070270354-A1 Azasugar derivatives, heparanase inhibitors, method for preparing same, compositions containing same, use thereof HPSE, HAAO, HEXD BCHE 1409/4885REN 500/4885CTSV 1027/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.